Category: Health

KUALA LUMPUR, June 7 (Bernama) — Vielight Inc, a leader in brain photobiomodulation (PBM) technology, announced the primary site for its pivotal clinical trial, St. Michael’s Hospital in Toronto, has been activated.

The hospital is the first among the eight sites that will carry out the study.

Conducted across North America, the trial will be a randomised, placebo-controlled study involving 228 subjects with moderate to severe cognitive impairment due to Alzheimer’s disease.

The protocol of the study has been reviewed by the US Food and Drug Administration and Health Canada.

The device in investigation, called the ‘Vielight Neuro RX Gamma’, is based on Vielight’s proprietary PBM technology which directs near infrared light, pulsing at the gamma rate of 40 Hz, to selected regions of the brain.

The procedure is non-invasive and the device has been designed to be suitable for home-use.

Subject to regulatory clearance, the device will be indicated for Alzheimer patients with moderate to severe impairment, the group that demands the most care and has the largest economic burden.

The trial will be independently managed by the Applied Health Research Centre, a methodology centre affiliated with St Michael’s Hospital.

— BERNAMA

KUALA LUMPUR, May 29 (Bernama) — Blood bond. The Hoxworth Blood Center, a public institution belonging to the University of Cincinnati and Biolog-id have signed a partnership contract to manage blood products in Cincinnati, Ohio.

The blood centre has implemented the Biolog Transfusion®, an RFID Blood Supply Management solution in order to better track the flow of platelet concentrates and red blood cell concentrates.

The Biolog-id solution was first implemented in 2018 to focus on the distribution and inventory management of Platelet Concentrates between the centre and four nearby hospitals.

This year, it is also covering the Phenotyped Red Blood Cell Concentrates managed by the blood centre’s Immunohematology Reference Laboratory.

The laboratory provides testing and consultation to assist hospitals in solving patients’ red blood cell serological problems.

The implementation of the Biolog-Transfusion® in the Hoxworth Blood Center ensures the availability of platelet concentrates and their on-time delivery while reducing the risk of wastage.

“As of today, we are satisfied with the Biolog-id solution for platelets, as well as their professional and committing team,” said blood centre director, Jose A. Cancelas.

Extension on the overall blood product production and supply is under consideration by the Hoxworth Blood Center.

— BERNAMA